Clinical Trials Browser

Phase 1/2 × Malignant Solid Tumour × Bevacizumab × Clear all

NCT02857920 2020-09-14

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Malignant Solid Tumour